17β-Estradiol Potentiates the Reinstatement of Cocaine Seeking in Female Rats: Role of the Prelimbic Prefrontal Cortex and Cannabinoid Type-1 Receptors by Doncheck, Elizabeth M. et al.
Marquette University
e-Publications@Marquette
Biomedical Sciences Faculty Research and
Publications Biomedical Sciences, Department of
1-1-2018
17β-Estradiol Potentiates the Reinstatement of
Cocaine Seeking in Female Rats: Role of the
Prelimbic Prefrontal Cortex and Cannabinoid
Type-1 Receptors
Elizabeth M. Doncheck
Marquette University
Luke A. Urbanik
Marquette University
Margot C. DeBaker
Marquette University
Laura M. Barron
Marquette University
Gage T. Liddiard
Marquette University
See next page for additional authors
Accepted version. Neuropsychopharmacology, Vol. 43 (2018): 781-790. DOI. © 2018 Springer
Nature Publishing AG. Used with permission.
Sharable link provided by the Springer Nature SharedIt content-sharing initiative.
Authors
Elizabeth M. Doncheck, Luke A. Urbanik, Margot C. DeBaker, Laura M. Barron, Gage T. Liddiard, Jennifer J.
Tuscher, Karyn M. Frick, Cecilia J. Hillard, and John Mantsch
This article is available at e-Publications@Marquette: https://epublications.marquette.edu/biomedsci_fac/183
 Marquette University 
e-Publications@Marquette 
 
Biomedical Science Faculty Research and Publications/College of Health 
Sciences 
 
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The 
published version may be accessed by following the link in th citation below. 
 
Journal/Monograph, Vol. xx, No. x (xxxx): XX-XX. DOI. This article is © [publisher] and permission has 
been granted for this version to appear in e-Publications@Marquette. [publisher] does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from [publisher].  
 
17β-Estradiol Potentiates the Reinstatement 
of Cocaine Seeking in Female Rats: Role of the 
Prelimbic Prefrontal Cortex and Cannabinoid 
Type-1 Receptors 
 
Elizabeth M Doncheck 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
Luke A Urbanik 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
Margot C DeBaker 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
Laura M Barron 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
Gage T Liddiard 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
Jennifer J Tuscher 
Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 
Karyn M Frick 
Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 
Cecilia J Hillard 
Department of Pharmacology and Toxicology and Neuroscience Research Center, Medical College of 
Wisconsin, Milwaukee, WI 
John R Mantsch 
Department of Biomedical Sciences, Marquette University, Milwaukee, WI 
 
Abstract 
Clinical observations imply that female cocaine addicts experience enhanced relapse vulnerability compared 
with males, an effect tied to elevated estrogen phases of the ovarian hormone cycle. Although estrogens can 
enhance drug-seeking behavior, they do not directly induce reinstatement on their own. To model this 
phenomenon, we tested whether an estrogen could augment drug-seeking behavior in response to an ordinarily 
subthreshold reinstatement trigger. Following cocaine self-administration and extinction, female rats were 
ovariectomized to isolate estrogen effects on reinstatement. Although neither peak proestrus levels of the 
primary estrogen 17β-estradiol (E2; 10 μg/kg, i.p., 1-h pretreatment) nor a subthreshold cocaine dose 
(1.25 mg/kg, i.p.) alone were sufficient to reinstate drug-seeking behavior, pretreatment with E2 potentiated 
reinstatement to the ordinarily subthreshold cocaine dose. Furthermore, E2 microinfusions revealed that E2 
(5 μg/0.3 μl, 15-min pretreatment) acts directly within the prelimbic prefrontal cortex (PrL-PFC) to potentiate 
reinstatement. As E2 has been implicated in endocannabinoid mobilization, which can disinhibit PrL-PFC 
projection neurons, we investigated whether cannabinoid type-1 receptor (CB1R) activation is necessary for E2 
to potentiate reinstatement. The CB1R antagonist AM251 (1 or 3 mg/kg, i.p., 30-min pretreatment) 
administered prior to E2 and cocaine suppressed reinstatement in a dose-dependent manner. Finally, PrL-PFC 
AM251 microinfusions (300 ng/side, 15-min pretreatment) also suppressed E2-potentiated reinstatement. 
Together, these results suggest that E2 can augment reactivity to an ordinarily subthreshold relapse trigger in a 
PrL-PFC CB1R activation-dependent manner. 
Introduction 
Correlational clinical studies suggest that cocaine-dependent females experience greater relapse vulnerability 
than males. Females experience greater difficulty abstaining (Gallop et al, 2007), relapse incidence (Ong et al, 
2005), and periods of resumed use following relapse (Carpenter et al, 2006). This heightened vulnerability is 
therefore a crucial, yet currently untreated, women’s health issue. Although women may be more vulnerable to 
relapse, the neurobiological basis for this sex difference is poorly characterized. 
A primary contributor to sex differences in relapse is the ovarian hormone cycle. Elevated estrogens left 
unopposed by progesterone correspond to increased drug cue-elicited craving (Sinha et al, 2007; Anker and 
Carroll, 2011), impulsive reward-seeking (Reimers et al, 2014), and positive subjective effects of cocaine (Evans 
and Foltin, 2006; Terner and de Wit, 2006). Preclinical studies using the self-administration/reinstatement 
procedure demonstrate higher levels of reinstatement during proestrus, when 17β-estradiol (E2) levels peak in 
the rodent estrous cycle (Feltenstein et al, 2011), and estrus, when E2 levels are moderate while progesterone 
remains low (Kippin et al, 2005; Feltenstein and See, 2007). Reinstatement is, furthermore, facilitated by 
chronically elevated E2 (Larson et al, 2005). In clinical studies, the higher estrogens and basal progesterone of 
the follicular phase correspond to greater psychostimulant responsiveness relative to the luteal phase (Terner 
and de Wit, 2006), and E2 administration during the follicular phase augments the euphoric effects of 
psychostimulants (Justice and de Wit, 2000). Though these data suggest that elevated estrogens promote the 
enhanced relapse vulnerability exhibited by females, the mechanisms whereby these effects are produced, and 
in which brain regions, are not well understood. 
One brain region implicated in relapse is the prelimbic prefrontal cortex (PrL-PFC). A glutamatergic projection 
from the PrL-PFC to the nucleus accumbens represents a key pathway through which stimuli trigger relapse to 
cocaine use (Kalivas and Volkow, 2005). Cocaine administration directly into the PrL-PFC is sufficient to trigger 
reinstatement (Park et al, 2002), while inhibition of the PrL-PFC using tetrodotoxin (Capriles et al, 2003), 
baclofen/muscimol (McFarland et al, 2003), or optogenetic-based manipulations (Stefanik et al, 2013) prevents 
cocaine-primed reinstatement. Notably, enhanced cocaine seeking in females corresponds to heightened PrL c-
fos reactivity (Zhou et al, 2014), an effect likewise elicited by elevated E2 (Wang et al, 2004). Thus the PrL-PFC 
represents a likely site for estrogens to promote cocaine seeking. 
Endocannabinoids are important regulators of PrL-PFC neuronal excitability (Hill et al, 2011; Martin-Garcia et al, 
2016). We have previously reported that glucocorticoids attenuate inhibitory constraint on PrL-PFC pyramidal 
neurons via mobilization of the endocannabinoid 2-arachidonoylglycerol and activation of cannabinoid type-1 
receptors (CB1Rs) that regulate GABAergic interneurons (Hill et al, 2011). As E2 has also been reported to 
mobilize endocannabinoids (Huang and Woolley, 2012; Tabatadze et al, 2015, Peterson et al, 2016), 
endocannabinoid signaling via PrL-PFC CB1Rs represents a potential mechanism by which estrogens influence 
cocaine-seeking behavior. 
We hypothesized that, in females, estrogens augment reactivity to triggers for cocaine use, thereby conferring 
enhanced relapse vulnerability. To test this hypothesis, we used a variation of the preclinical self-
administration/reinstatement procedure, which has predictive validity for relapse in humans (Epstein et al, 
2006), wherein proestrus-level E2 potentiates reinstatement of drug seeking to an ordinarily subthreshold dose 
of cocaine. To investigate the role of the PrL-PFC in E2 effects on cocaine seeking, we tested the sufficiency of 
intra-PrL E2 injections for potentiating cocaine-primed reinstatement. Moreover, to determine the involvement 
of endocannabinoid signaling, we tested the effect of CB1R antagonism, systemically and intra-PrL-PFC, on E2-
potentiated cocaine seeking. 
Materials and methods 
Subjects 
Sexually mature female Sprague Dawley rats (90-day old/250 g minimum at study onset) obtained from Envigo 
(Indianapolis) were single-housed under a reversed 12 : 12 light–dark cycle (lights off at 0700 hours) with ad 
libitumaccess to standard rat chow and water. Experiments were performed in the dark phase and in 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, Eighth 
edition. All experiments were approved by the Marquette University Institutional Animal Care and Use 
Committee. 
Catheterization and Cannulation 
Rats were surgically implanted with intracranial cannulae and indwelling intravenous catheters for cocaine self-
administration as previously described (Graf et al, 2013; McReynolds et al, 2016), with minor adaptations. 
See Supplementary Methods for more information. 
Cocaine Self-Administration, Extinction, and Reinstatement Testing 
All self-administration experimental procedures were conducted as previously described (Graf et al, 
2013; McReynolds et al, 2016), with minor adaptations. Briefly, females underwent daily 2-h cocaine self-
administration sessions for 10–14 days, followed by extinction training under identical conditions. Following 
establishment of extinction criterion, all females were surgically OVXed prior to reinstatement except for one 
cohort tested across the ovarian hormone cycle. Extinction criterion was re-established between tests, which 
were administered in a counterbalanced design. See Supplementary Methods for more information. 
Ovariectomy (OVX) 
Bilateral surgical OVXs were conducted using a dorsal approach as previously described (Twining et al, 2013). 
See Supplementary Methods for more information. 
Drugs 
Cocaine hydrochloride was obtained through the National Institute on Drug Abuse Drug Supply Program. 2-
Hydroxypropyl-β-cyclodextrin (HBC), HBC-encapsulated E2, and AM251 were purchased from Sigma-Aldrich. 
Cocaine, E2, and HBC were dissolved in 0.9% bacteriostatic saline. Systemic AM251 was first dissolved in 100% 
ethanol and then in Cremaphor and saline in a 1 : 1 : 18 ratio. Intra-PrL AM251 was first dissolved in DMSO and 
then saline in a 1 : 9 ratio. 
Statistics 
Statistical analyses were conducted using the SPSS software and consisted of unpaired t-tests or one- or two-
way repeated-measures ANOVAs followed by Bonferroni-corrected post hoc and paired t-test analyses when 
appropriate. Statistical significance was defined as P<0.05 for all analyses. 
Estrous-Phase Determination and Recapitulation 
Estrous phase was monitored daily by vaginal lavage, with blood samples simultaneously collected by 
intravenous catheter (see Supplementary Methods). Blood samples were also collected from OVXed females 
given E2 (10, 50, or 100 μg/kg, i.p.; 1-h pretreatment) or vehicle. To identify a proestrus-recapitulating dose, 
plasma E2 levels were compared following ELISA measurement (Cayman Chemicals) conducted per the 
manufacturer’s protocol. 
Experiment 1: E2-Potentiated Reinstatement of Cocaine Seeking 
Female rats received intravenous catheters and underwent cocaine self-administration and extinction training. 
To avoid effects on self-administration and extinction and isolate effects on reinstatement, rats did not undergo 
OVX until after establishing extinction criterion. Following recovery and extinction criterion re-establishment, a 
counterbalanced design was used to administer the following drug treatments (n=5): E2 (10 μg/kg, i.p.; 1-h 
pretreatment)/saline, HBC/saline, E2/cocaine (0.625, 1.25, or 2.5 mg/kg, i.p.), and HBC/cocaine. Animals were 
re-extinguished to criterion between tests. 
Experiment 2: Intra-PrL E2-Potentiated Reinstatement of Cocaine Seeking 
Female rats were surgically implanted with intravenous catheters and bilateral intra-cranial cannulae targeting 
the PrL-PFC prior to self-administration and extinction. Following extinction establishment, surgical OVX, and 
then extinction re-establishment, females were tested for reinstatement under the following four conditions 
(n=9): intra-PrL E2 (5 μg/side.; 15-min pretreatment)/saline, intra-PrL HBC/saline, intra-PrL E2/cocaine 
(1.25 mg/kg, i.p.), and intra-PrL HBC/cocaine. Following study completion, cannulae placements were assessed 
(see Supplementary Methods) and anatomical misses were excluded from the study (n=2). 
Experiment 3: CB1R Activation Role in E2-Potentiated Reinstatement 
To investigate CB1R involvement in E2-potentiated reinstatement, females underwent cocaine self-
administration, extinction, and OVX prior to reinstatement testing under the following five conditions (n=7): 
vehicle/E2 (10 μg/kg, i.p.; 1-h pretreatment)/saline; vehicle/HBC/saline; vehicle/HBC/cocaine (1.25 mg/kg, i.p.), 
vehicle/E2/cocaine, and AM251 (1 or 3 mg/kg, i.p.; 30-min pretreatment)/E2/cocaine. 
To determine whether CB1R activation is necessary specifically for E2-potentiation effects, and not just the 
priming effects of cocaine, a group of rats was tested for AM251 effects on suprathreshold (eg, 5 mg/kg) 
cocaine-primed reinstatement. Following self-administration, extinction, and OVX, testing occurred under the 
following conditions (n=4): vehicle/cocaine (5 mg/kg, i.p.), AM251 (1 or 3 mg/kg, i.p., 30-min 
pretreatment)/cocaine. 
To determine whether PrL-PFC CB1R activation contributes to E2-potentiated reinstatement, rats underwent 
catheterization and bilateral intra-PrL cannulation, self-administration, extinction, and OVX prior to 
reinstatement testing under the following five conditions (n=7): intra-PrL vehicle/HBC/saline; intra-PrL 
vehicle/E2 (10 μg/kg, i.p.; 1-h pretreatment)/saline; intra-PrL vehicle/HBC/cocaine (1.25 mg/kg, i.p.); intra-PrL 
vehicle/E2/cocaine, and intra-PrL AM251 (300 ng/side, 15-min pretreatment)/E2/cocaine. A higher AM251 dose 
(1 μg/0.3 μl/side) was also tested, but the increased DMSO concentration (70%) required to solubilize the drug 
had non-specific disruptive effects on behavior. Following study completion, cannulae placements were 
assessed. No anatomical misses were found. 
Results 
Estrous-Phase Determination and Recapitulation 
To identify a proestrus-recapitulating dose, E2 blood levels were measured by ELISA across the estrous cycle 
(proestrus n=21, estrus n=13, metestrus n=13, diestrus n=11). We found peak pmol/ml E2 levels 
(33.9±15.8 pg/ml) during proestrus (Figure 1). Next, trunk blood was collected from OVXed females following E2 
replacement (0 μg/kg n=4, 10 μg/kg n=8, 50 μg/kg n=7, 100 μg/kg n=3; 1-h pretreatment). E2 injections dose-
dependently increased blood levels (Figure 1), with 10 μg/kg E2 approximating proestrus levels (unpaired t-
test; t(27)=0.3853, p=0.7030) and both 50 (t(26)=3.724, p<0.001) and 100 μg/kg E2 (t(22)=3.303, p<0.01) 
surpassing physiological levels. We, therefore, conducted testing for E2-potentiated reinstatement using 
10 μg/kg E2. 
 
Figure 1 Proestrus-level E2 recapitulation. Circulating E2 plasma levels corresponding to each estrous phase in gonadally 
intact females compared with plasma levels evoked by E2 replacement in OVXed females. P = proestrus, E = estrus, M = 
metestrus, and D = diestrus. Data are represented as mean±SEM. **P<0.01, ***P<0.001 versus proestrus blood levels. 
 
Cocaine Self-Administration and Extinction 
A cocaine self-administration and extinction timeline is depicted in Figure 2a. Responding on the first and last 
day of self-administration and extinction is summarized for each experiment in Supplementary Table 
S1 (see Supplementary Materials). Female rats readily acquired cocaine self-administration and displayed 
extinction. Neither self-administration nor extinction varied significantly across experiments. 
 Figure 2 Proestrus-level E2 potentiates the reinstatement of cocaine seeking to subthreshold cocaine priming dose. 
Following re-establishment of extinction criterion post-ovariectomy, females were tested for reinstatement in response to a 
0.625, 1.25, and 2.5 mg/kg cocaine. (a) General timeline for cocaine self-administration and extinction training. (b) Timeline 
for reinstatement testing. Testing for the effects of 10 μg/kg E2 on (c) 0.625 mg/kg cocaine, (d) 1.25 mg/kg cocaine, and (e) 
2.5 mg/kg cocaine in OVXed females. Data are represented as mean±SEM. NS, not significant, *P <0.05. 
 
Experiment 1: E2-Potentiated Reinstatement of Cocaine Seeking in OVXed Females 
We initially tested for reinstatement across a cocaine dose–response curve to identify a subthreshold dose 
(n=5; Supplementary Figure S1). Similar to previous reports (Lynch and Carroll, 2000), we found 0.625 and 
1.25 mg/kg cocaine to be subthreshold and 2.5 and 5.0 mg/kg cocaine to be suprathreshold for reinstatement. 
To determine the effects of proestrus-level E2 on cocaine-induced reinstatement, we examined the effects of 
10 μg/kg E2 on reinstatement to 0.625 mg/kg (Figure 2c; n=5), 1.25 mg/kg (Figure 2c; n=5), and 2.5 mg/kg 
(Figure 2d; n=5) priming doses of cocaine; see Figure 2b for design. Significant reinstatement was not observed 
in animals treated with 10 μg/kg E2 alone. Similarly, significant reinstatement was not observed following 
0.625 mg/kg cocaine, either alone or in combination with 10 μg/kg E2 (Figure 2c). However, while 1.25 mg/kg 
cocaine alone did not reinstate cocaine seeking, robust reinstatement was observed when this dose was 
combined with E2 (n=5, Figure 2d). A two-way repeated-measures ANOVA showed significant main effects of 
day (extinction vs reinstatement; (F(1,4)=43.657, p<0.01), treatment (F(3,12)=7.015, p<0.01), and a significant 
interaction (F(3,12)=6.286, p<0.01). Post hoc tests revealed significant reinstatement responding relative to 
extinction only in the E2/cocaine condition (p<0.01). 
To determine whether the E2-potentiated reinstatement observed in OVXed females models reinstatement 
responding during proestrus, a cohort of gonadally intact females was tested for reinstatement to 1.25 mg/kg 
cocaine across the estrous cycle (Supplementary Figure S2). A two-way repeated-measures ANOVA revealed a 
significant interaction between day (extinction vsreinstatement) and estrous phase (F(3,14)=3.927, p<0.05), with 
higher responding during reinstatement relative to extinction in proestrus (p<0.05). 
Robust reinstatement was also observed in response to 2.5 mg/kg cocaine (Figure 2e). A two-way repeated-
measures ANOVA revealed significant main effects of day (extinction vs reinstatement, F(1,4)=28.297, p<0.01), 
treatment (F(3,12)=12.439, p<0.001), and a significant interaction (F(3,12)=7.155, p<0.01). Post hoc tests revealed 
significant responding during reinstatement relative to extinction following both HBC/cocaine (p<0.01) and 
E2/cocaine (p<0.05). Although not statistically significant, higher reinstatement responding was observed in the 
E2/cocaine condition compared with HBC/cocaine. 
We also determined the relationship between E2 dose (0, 10, 50, and 100 μg/kg, i.p.; 1-h pretreatment) and 
reinstatement to subthreshold cocaine (0.625 mg/kg, i.p.; Supplementary Figure S3). A two-way repeated-
measures ANOVA revealed a significant interaction between day and treatment (F(3,12)=5.630, p<0.05). The E2 
effects on reinstatement were dose-dependent, as post hoc tests revealed significant responding during 
reinstatement relative to extinction following 100 μg/kg E2/cocaine (p<0.05). 
Experiment 2: Intra-PrL E2-Potentiated Reinstatement of Cocaine Seeking in OVXed 
Females 
To investigate the PrL-PFC contribution to E2-potentiated reinstatement, we determined the ability of bilateral 
intra-PrL E2 injections (5 μg/0.3 μl/side; 15-min pretreatment) to potentiate cocaine seeking in response to 
1.25 mg/kg cocaine (n=7; see Figure 3a for design). As with systemic E2, neither intra-PrL E2 nor 1.25 mg/kg 
cocaine alone reinstated cocaine seeking, but robust reinstatement was observed with their combination (Figure 
3b). A two-way repeated-measures ANOVA showed a main effect of day (extinction vs reinstatement, 
F(1,6)=7.970, p<0.05), treatment (F(3,18)=3.317, p<0.05), and a significant interaction (F(3,18)=4.633, p<0.05). Post 
hoc tests revealed significant responding during reinstatement relative to extinction in the intra-PrL PFC 
E2/cocaine condition (p<0.05). Intra-PrL E2/vehicle cannulae placements are depicted in Figure 3c, and a 
representative PrL histology image is shown in Figure 3d. 
 
Figure 3 Intra-PrL E2 potentiates the reinstatement of cocaine seeking to subthreshold cocaine priming dose. Following re-
establishment of extinction criterion post-ovariectomy, females were tested for reinstatement in response to intra-PrL E2 
and 1.25 mg/kg cocaine. (a) Timeline for intra-PrL E2-potentiated reinstatement. (b) Testing for the effects of intra-PrL 
5 μg/0.3 μl E2 on reinstatement in response to 1.25 mg/kg OVXed females. (c) PrL cannulae placements for intra-PrL E2 
microinfusions. (d) Representative histology image of PrL cannulae placements. Data are represented as mean±SEM. 
*P<0.05. 
 
Experiment 3: Role of CB1R Activation in E2-Potentiated Reinstatement 
We previously reported a role for endocannabinoid signaling via CB1Rs in corticosterone-potentiated cocaine-
primed reinstatement in male rats (McReynolds et al, 2016). To determine whether CB1R activation has a similar 
role in E2-potentiated reinstatement, female rats were tested for E2-potentiated reinstatement following 
pretreatment with the CB1R inverse agonist, AM251 (see Figure 4a for design). AM251 pretreatment (1 or 
3 mg/kg, i.p.; 30-min pretreatment) prior to E2 (10 μg/kg, 1-h pretreatment) and cocaine (1.25 mg/kg) dose-
dependently reduced potentiated reinstatement (n=7; Figure 4b). A two-way repeated-measures ANOVA 
showed significant main effects of day (extinction vs reinstatement; F(1,6)=9.373, p<0.05), treatment 
(F(5,30)=3.000, p<0.05), and a significant interaction (F(5,30)=3.948, p<0.01). Post hoc testing revealed significant 
responding during reinstatement relative to extinction only in the vehicle/E2/cocaine condition (p<0.05). 
Comparison across reinstatement test conditions using one-way repeated-measures ANOVA followed by post 
hoc testing revealed greater reinstatement in the vehicle/E2/cocaine condition relative to 3 mg/kg 
AM251/E2/cocaine (p<0.05). 
 
Figure 4 Necessity for CB1R activation in E2-potentiated reinstatement of cocaine seeking in OVXed females. (a) Timeline 
for CB1R antagonism in E2-potentiated reinstatement. (b) Testing for the effects of CB1R antagonism (AM251; 1 and 
3 mg/kg) on 10 μg/kg E2-potentiated reinstatement to 1.25 mg/kg cocaine in OVXed females. (c) Timeline for CB1R 
necessity in cocaine-primed reinstatement. (d) Testing for the requirement of CB1R activation (AM251; 1 and 3 mg/kg) in 
5 mg/kg cocaine-primed reinstatement in OVXed females. (e) Timeline for intra-PrL CB1 antagonism in E2-potentiated 
reinstatement. (f) Testing for E2-potentiated reinstatement following intra-PrL CB1 (AM251; 300 ng/0.3 μl) antagonism. (g) 
PrL cannulae placements for intra-PrL CB1 antagonist microinfusions. (h) Representative histology image of PrL cannulae 
placements. Data are represented as mean±SEM. *P<0.05. 
 
To determine whether CB1R activation is necessary specifically for E2 effects, or for cocaine-primed 
reinstatement generally, rats (n=4) received systemic AM251 (1 or 3 mg/kg, i.p.) or vehicle prior to testing for 
reinstatement in response to suprathreshold cocaine (5 mg/kg, i.p.; see Figure 4c for design). AM251 
pretreatment did not suppress reinstatement to suprathreshold cocaine (Figure 4d). Two-way ANOVA showed 
main effects of day (extinction vs reinstatement; F(1,3)=39.256, p<0.01), but no effects of treatment or 
interactions. Post hoc tests did not reveal significant differences in reinstatement responding between 
conditions. 
To determine whether PrL-PFC CB1R activation is necessary for E2-potentiated reinstatement, rats (n=7) 
received bilateral PrL-PFC AM251 (0.3 μg/0.3 μl/side; 15-min pretreatment) or vehicle injections prior to testing 
for reinstatement in response to E2 (10 μg/kg; 1-h pretreatment) and low-dose cocaine (1.25 mg/kg; see Figure 
4e for design). Intra-PrL AM251 significantly attenuated, but did not fully block, E2-potentiated reinstatement 
(Figure 4f). A two-way repeated-measures ANOVA revealed a trend towards a main effect of day 
(extinction vs reinstatement; F(1,6)=4.450, p=0.079), a significant main effect of treatment (F(4,24)=6.449, p<0.001), 
and an interaction between reinstatement and treatment (F(4,24)=3.609, p<0.05). Post hoc testing revealed 
significant responding during reinstatement relative to extinction under the intra-PrL PFC vehicle/E2/cocaine 
condition (p<0.01). Comparison across reinstatement test conditions using one-way repeated-measures ANOVA 
followed by post hoc testing revealed greater reinstatement in the vehicle/E2/cocaine condition relative to 
vehicle/HBC/saline (p<0.001), vehicle/E2/saline (p=0.05), and vehicle/HBC/cocaine (p<0.05). However, no 
statistically significant differences were observed between the AM251/E2/cocaine condition and the other 
reinstatement conditions. Intra-PrL AM251/vehicle cannulae placements are depicted in Figure 4g, and a 
representative PrL histology image is shown in Figure 4f. 
Discussion 
We demonstrated that acute proestrus-level E2 potentiates cocaine seeking in OVXed female rats, in part via 
PrL-PFC CB1R-dependent actions. We found that E2 (10 μg/kg, i.p.) alone is insufficient to reinstate cocaine 
seeking but does potentiate reinstatement in response to ordinarily subthreshold cocaine (1.25 mg/kg, i.p.). 
These findings align with prior reports of greater propensity to drug seeking during heightened estrogen phases 
(Kippin et al, 2005; Feltenstein et al, 2011; Feltenstein and See, 2007) and are consistent with our own 
observation of reinstatement to subthreshold cocaine only during proestrus. Moreover, they extend a report 
that 9 days of E2 administration promotes cocaine-primed reinstatement in OVXed female rats (Larson et al, 
2005) by demonstrating that acute E2 is sufficient to promote cocaine seeking. The observation that peak 
physiological E2 levels can ‘set the stage’ for drug seeking in females is akin to our prior findings that stress-
response level corticosterone also potentiates cocaine-primed reinstatement in males (Graf et al, 
2013; McReynolds et al, 2016). 
PrL-PFC E2 Actions 
The E2 influence on cocaine seeking likely involves the PrL-PFC. Intra-PrL E2 injections reproduced the 
potentiating effects of proestrus-level E2 on cocaine seeking. As activation of PrL-PFC glutamatergic projections 
to the nucleus accumbens is critical for cocaine-primed reinstatement (Capriles et al, 2003; McFarland et al, 
2003; Kalivas and Volkow, 2005; Stefanik et al, 2013), we hypothesize that E2 acts within the PrL-PFC to facilitate 
activation of this pathway, likely by enhancing pyramidal neuron excitability. Accordingly, E2 both enhances 
excitation (Oberlander and Woolley, 2016) and suppresses inhibition (Huang and Woolley, 2012; Tabatadze et 
al, 2015) of pyramidal neurons in other brain regions. Furthermore, basal PFC dopamine levels fluctuate in an 
estrous cycle-dependent manner (Dazzi et al, 2007). Finally, heightened PFC c-fos activity corresponds to 
elevated E2 levels (Wang et al, 2004) and augmented cocaine seeking in females (Zhou et al, 2014). Thus we 
hypothesize that low-dose cocaine produces an excitatory drive on accumbens-projecting PrL pyramidal neurons 
that is subthreshold for pathway activation, except within an elevated E2 context. 
It is unclear whether findings derived using a cocaine-primed reinstatement procedure can extend to other 
reinstatement triggers. Although the PrL-PFC appears generally important for drug-seeking behavior (Kalivas and 
Volkow, 2005), the neural circuitry underlying cocaine-primed reinstatement may differ from context-, cue-, and 
stress-induced reinstatement (e.g., Lasseter et al, 2010). Future studies will investigate the ability of E2 to 
potentiate reactivity to other triggers. 
Endocannabinoid Signaling: Estrogen Regulation 
E2 could modulate PrL-PFC neuronal excitability through endocannabinoid signaling regulation. Estrogens have 
been reported to mobilize endocannabinoids (El-Talatini et al, 2010; Huang and Woolley, 2012; Tabatadze et al, 
2015; Peterson et al, 2016) and regulate CB1R binding (Rodriguez de Fonseca et al, 1994; Castelli et al, 
2014; Riebe et al, 2010). PrL-PFC CB1Rs in females are expressed on the same interneuron terminals that exert 
tonic inhibitory constraint on pyramidal neurons in males (Chiu et al, 2010; Hill et al, 2011), and in males, PrL-
PFC CB1R activation suppresses this GABAergic inhibition (Hill et al, 2011). In the present study, systemic CB1R 
antagonism (AM251; 1 or 3 mg/kg, i.p.) suppressed E2-potentiated reinstatement in a dose-dependent manner, 
demonstrating that E2 effects on cocaine seeking are attributable to endocannabinoid mobilization and CB1R 
activation. By contrast, the same AM251 doses failed to block reinstatement to suprathreshold cocaine 
(5 mg/kg, i.p.), consistent with our previous findings in males (McReynolds et al, 2016), indicating that, while 
CB1R activation mediates the E2 influence on cocaine seeking, it is not required for cocaine-primed 
reinstatement in the absence of elevated E2 levels. The PrL-PFC endocannabinoid signaling contribution to E2-
potentiated cocaine seeking was tested by administering PrL-PFC AM251 prior to E2 and cocaine, which 
suppressed E2-potentiated reinstatement. E2-induced CB1R-mediated suppression of inhibition may, therefore, 
render the PrL-PFC more excitable by ordinarily subthreshold triggers and thus enhance relapse vulnerability. 
E2-Potentiated Reinstatement: Alternative Mechanisms 
Although PrL-PFC CB1R antagonism attenuated E2-potentiated cocaine seeking, in contrast to systemic AM251, 
intra-PrL-PFC AM251 failed to fully block potentiated reinstatement. There are several reasons why this may 
have occurred. First, we were unable to test AM251 concentrations >0.3 μg/side due to solubility issues, as the 
greater DMSO concentrations required to solubilize AM251 suppressed reinstatement under vehicle control 
conditions (data not reported). Thus it is possible that we were unable to achieve complete PrL-PFC CB1R 
antagonism. Second, the ability of E2 to produce widespread effects throughout the brain suggests that E2-CB1R 
effects in multiple brain regions, such as the nucleus accumbens and ventral tegmental area, may converge to 
enhance cocaine seeking during heightened estrogen periods. For example, E2 has been reported to produce 
CB1R-dependent effects on nucleus accumbens spine density, which correspond to cocaine sensitization 
(Peterson et al, 2016). Third, E2 regulation of the HPA axis could contribute to its effects on cocaine seeking. 
17β-Estradiol stimulates corticosterone release (Lo et al, 2000; Niyomchai et al, 2005; Weiser and Handa, 2009), 
and corticosterone attenuates PrL-PFC inhibitory synaptic transmission via endocannabinoid mobilization and 
CB1R activation (Hill et al, 2011) and potentiates reinstatement in a CB1R-dependent manner in males 
(McReynolds et al, 2016). However, as intra-PrL E2 recapitulates the systemic E2 effects on cocaine seeking, it is 
unlikely that E2-induced HPA axis activation exclusively accounts for its effects on reinstatement. 
Although the receptor mechanism through which PrL-PFC E2 acts to promote cocaine seeking is unclear, the 
rapid effects suggest a non-genomic mechanism of action. Estrogen receptor-α (ERα), estrogen receptor-β (ERβ), 
and G-protein-coupled estrogen receptor-1 (GPER1) are all expressed in the PFC and, although primarily 
localized to presynaptic axon terminals, they are also found in dendrites where they could regulate 
endocannabinoid production (Almey et al, 2014). In the hippocampus, E2 activation of ERα mobilizes the 
endocannabinoid, N-arachidonoylethanolamine, via interaction with mGluR1, resulting in a CB1R-dependent 
attenuation of GABA release in females (Huang and Woolley, 2012; Tabatadze et al, 2015). The CB1R-dependent 
ability of E2 to promote behavioral sensitization also requires an ERα–mGluR1 interaction (Peterson et al, 2016). 
However, it is unknown whether similar regulation occurs in the PFC. ERβincreases presynaptic glutamate 
transmission in the female rat hippocampus (Oberlander and Woolley, 2016) and is required for potentiation of 
excitatory synaptic transmission in the female mouse hippocampus (Galvin and Ninan, 2014). Moreover, chronic 
ERβ, but not ERα, activation promotes cocaine-primed reinstatement in female rats (Larson and Carroll, 2007). 
However, it is unclear how ERβ-induced endocannabinoid signaling could increase excitatory synaptic function. 
Although GPER1 activation increases postsynaptic glutamate sensitivity (Oberlander and Woolley, 2016), effects 
on endocannabinoid signaling have not been reported. 
OVX and Physiological E2 Considerations 
One caveat of the present study was that rats were surgically ovariectomized to permit precise control over E2 
levels during reinstatement testing. Importantly, to avoid effects on cocaine self-administration (Zhao and 
Becker, 2010; Lynch and Taylor, 2005) and extinction (Twining et al, 2013) that could later confound 
reinstatement, rats underwent OVX after self-administration and extinction and just before reinstatement 
testing. The purpose of the experiment was to reproduce proestrus-level E2 and assess effects on cocaine 
seeking. However, we did not directly compare the effects of the proestrus E2 dose with lower E2 doses that 
recapitulate other estrous cycle phases. We did, however, demonstrate that potentiated reinstatement is only 
observed in response to 1.25 mg/kg cocaine during proestrus in gonadally intact females and that the E2 effects 
on cocaine seeking are dose-dependent, as supraphysiological E2 levels further augmented reinstatement 
vulnerability. Additionally, chronic OVX has been shown to attenuate cocaine-primed reinstatement (Larson et 
al, 2005; Larson and Carroll, 2007), so elevating E2 in the face of chronically depleted estrogens likely has 
differential consequences for cocaine seeking than what is observed in intact cycling rats in proestrus. Indeed, 
OVX produces neuroadaptations that could modulate behavior, including CB1R and ER binding and expression 
changes in brain regions associated with cocaine seeking (Rodriguez de Fonseca et al, 1994; Riebe et al, 
2010; Castelli et al, 2014; Rose’Meyer et al, 2003; Bastos et al, 2015). Moreover, we report higher proestrus E2 
levels in cocaine-naive females than those reported following self-administration (Feltenstein and See, 2007), 
suggesting that a dose recapitulating cocaine-naive proestrus E2 levels could prove supraphysiological in 
cocaine-experienced OVX females. However, whether E2 levels are persistently suppressed following self-
administration is unknown. 
Progesterone Influence Over Relapse 
Although the present findings implicate E2 as a key determinant of sex and cycle-related influences on cocaine 
use, other sex hormones are also likely involved. Most notably, while estrogens may act to enhance relapse 
vulnerability, progesterone may provide protection against it (Sofuoglu et al, 2002; Evans and Foltin, 2006; Sinha 
et al, 2007). Higher reinstatement responding is observed during low progesterone phases (Feltenstein and See, 
2007). Future experiments will examine how covariation in E2 and progesterone levels relate to reinstatement 
vulnerability. 
Conclusions 
Taken together, our findings provide evidence that high estrogen brain states can promote cocaine seeking 
through endocannabinoid signaling regulation and PrL-PFC actions. These findings have implications for 
understanding sex differences in relapse vulnerability and variation in propensity to seek cocaine across the 
reproductive cycle in women. Moreover, as recent clinical findings suggest that, compared with men, women 
diagnosed with substance use disorder exhibit different sensitivity and responsiveness to some medications (Fox 
et al, 2013, 2014), the ability of E2 to regulate endocannabinoid signaling in females may guide the development 
of sex-specific treatment approaches aimed at relapse prevention. 
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Supplemental Materials and Methods 
Estrous phase determination and recapitulation: Estrous phase was monitored daily by vaginal lavage. Vaginal 
epithelial cells were collected by distilled water lavage every 24-hrs for 3-wks and stained using Papanicolau 
(Sigma) and hematoxylin (Vector) reagents.  Cell types were visualized and differentiated under a Nikon 55i 
Eclipse microscope using Nikon NIS Elements, and the ratio of three cell types was used to determine estrous 
phase.  Briefly, proestrus was defined by predominant presence of large round nucleated epithelial cells, estrus 
by large cornified epithelial cells, diestrus by leukocytes, and metestrus by a mixture of the three.  Blood 
samples were simultaneously collected by intravenous catheter for measurement of circulating E2 levels across 
the estrous cycle.  OVX’ed females were given E2 (10, 50, or 100 µg/kg, i.p.; 1-hr pretreatment) or vehicle 
followed by trunk blood collection for E2 measurement.  All blood samples were centrifuged at 1000 x g for 10-
min, and plasma supernatant collected and stored at -80° for later analysis.  To identify a proestrus-
recapitulating dose, plasma E2 levels were measured using an acetylcholinesterase-linked ELISA (Cayman 
Chemicals) per the manufacturer protocol. 
Intravenous catheterization and intracranial cannulation: Rats were surgically implanted with indwelling 
intravenous catheters for cocaine self-administration as previously described (Graf et al, 2013; McReynolds et al, 
2016) with minor adaptations.  The tubing length [Silastic; Dow Corning; (0.6-mm i.d.×1.1-mm o.d.) x 40-mm] 
was shortened to 6-cm between the back-mounted cannula (Plastics One) and vein insertion point, and then 
flat-cleaved to 3.1-cm between the vein insertion point and distal end prior to implantation, to accommodate 
for the smaller female body size.  Rats received carprofen analgesics (2 mg/5 g tablet/day for 3-d) following 
surgery, and intravenous cefazolin antibiotics (0.2 mg/day for 5-d) thereafter.  Following 1-wk of recovery, rats 
initiated cocaine self-administration training.  At the time of catheterization, some rats received bilateral 11-
mm, 26-gauge cannula aimed 0.5-mm above the PrL-PFC, and the following coordinates were used: 
anteroposterior (A/P), +2.8-mm; mediolateral (M/L), +1.0-mm; dorsoventral (D/V), -3.5-mm at 8°. All surgeries 
were conducted under ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg/0.65mL, i.p.) anesthesia. 
Cocaine self-administration: All self-administration experimental procedures were conducted in operant 
conditioning chambers, fitted with retractable levers and cue lights, housed in sound-attenuating compartments 
(Med Associates, Inc.).  Rats were initially trained to press an active lever, with an associated reward availability 
cue light, under a fixed-ratio (FR) 1 schedule for sucrose pellet rewards.  Following acquisition of lever pressing, 
the rats were transitioned to self-administer cocaine (0.5 mg/kg/0.2 mL infusion) during daily 2-hr sessions.  
Infusions were delivered over the course of 5-sec, followed by a 10-sec time-out period during which lever 
pressing was not reinforced and the cue light above the active lever switched off.  Responding on an 
unrewarded, inactive lever was also recorded.  Once stable high responding (>20 infusions/2-hr session) was 
maintained under an FR4 schedule of reinforcement for 10-14 days, the cocaine syringe was replaced with saline 
and animals underwent extinction training. 
Extinction training: Following maintained cocaine self-administration, rats were subjected to identical conditions 
as before except lever responding resulted in saline infusions instead of cocaine.  Once responding dropped 
below extinction criterion (<15 total lever presses/2-hr session for 2 of 3 last consecutive sessions), rats 
underwent surgical ovariectomy.  Following a 1-wk recovery period, animals reinitiated extinction sessions until 
criterion was reestablished.   
Surgical ovariectomy (OVX):  Bilateral surgical OVXs were conducted using a dorsal approach as previously 
described (Twining et al, 2013).  Following anesthesia, a 2-cm horizontal incision was cut through the skin on the 
midline approximately 3-cm anterior to the iliac crests.  Then, using that incision as a moveable window, 
bilateral 0.5-cm incisions were made through the muscle approximately 1.25-cm above and 2-cm lateral to the 
iliac crests.  Blunt forceps were used to visualize and gently externalize the ovaries, which were then clamped off 
at the oviduct with a hemostat.  Non-absorbable suture thread was used to tie off the oviduct and associated 
blood vessels below the hemostat. The ovary was then excised, the hemostat unclamped, and the integrity of 
the sutures assessed prior to replacing the tissue into the peritoneum and closing. 
Reinstatement testing: Following reestablishment of extinction criterion, animals underwent reinstatement 
testing.  Reinstatement conditions were identical to extinction, except for hormonal and/or cocaine pre-
treatment.  Tests were administered in a counterbalanced design, and extinction criterion reestablished 
between tests. 
Cannulae placement checks: Following study completion, brains were fixed with 4% paraformaldehyde and cryo-
protected with 30% sucrose. Subsequently, brains were blocked and sliced into 50-µM coronal sections on a 
cryostat, and stained with cresyl violet to confirm cannula placement.  Anatomical misses were excluded from 
the study. 
Experiment S1: Cocaine-primed reinstatement dose-response curve: Following self-administration, extinction, 
and recovery from surgical ovariectomy, we tested a cohort of females for reinstatement to a range of cocaine-
priming doses.  To study the enhancing effects of E2 on reinstatement responding, we first identified a priming 
dose of cocaine (1.25 mg/kg, i.p.) that was sub-threshold for reinstatement.  Finding that, we also tested higher 
supra-threshold (2.5 and 5.0 mg/kg, i.p.) and lower sub-threshold (0.625 mg/kg, i.p.) priming doses.   
Experiment S2: Proestrus-potentiation of reinstatement: Following extinction, gonadally-intact females were 
tested for reinstatement in response to sub-threshold cocaine (1.25 mg/kg, i.p.) in a phase-agnostic manner.  
Estrous phase was monitored by vaginal lavage collected daily following extinction and reinstatement sessions.  
The influence of estrous phase on reinstatement responding was retroactively determined by subdividing 
reinstatement tests according to estrous phase.  
Experiment S3: Estrogen-potentiated reinstatement dose-response curve: Following extinction and recovery from 
surgical ovariectomy, females were tested for reinstatement in response to E2 and low sub-threshold cocaine 
(0.625 mg/kg, i.p.).  To determine whether heightened E2 levels could produce heightened reinstatement 
responding, animals were pretreated with an increasing range of E2 doses (0, 10, 50, and 100 µg/kg, i.p.; 1hr 
pretreatment) prior to cocaine administration.   
  
Supplemental Results 
Table S1: Data represent total active lever responses/2-h session for Figures 2, 3, 4, S1, and S2 during the first 
and last FR4-days of cocaine self-administration (SA) and on the first day and last day of extinction before 
reinstatement. The number of days to reach extinction criteria before ovariectomy for each experiment is also 
reported.  Data are represented as mean ± SEM.   
Table S1: Cocaine self-
administration and 
extinction responding 
     
 Cocaine Self-
Administration 
 Extinction  Extinction 
Duration 
Expe riment (n) First Day Last Day First Day Last Day # Days 
2      
10 E2/Cocaine; (5) 113 ± 7.4 150.8 ± 
41.7 
76.2 ± 16.6 8 ± 1.7 12 ± 1.9 
3      
PrL E2/1.25 Cocaine; (7) 127.4 ± 10.6 125.7 ± 
21.3 
46.7 ± 6.6 10.4 ± 1.5 13.6 ± 3.4 
4B      
AM251/E2/1.25 Cocaine (7) 178.3 ± 43.7 130.7 ± 
23.3 
85.4 ± 18.5 14.6 ± 1.5 17.7 ± 4.1 
4D      
AM251/5.0 Cocaine (4) 134.8 ± 50.6 104 ± 27.7 42.2 ± 14.4 12.3 ± 1.9 17.5 ± 4.4 
4F      
PrL AM251/E2/Cocaine; (7) 171.4 ± 31 97.6 ± 10.6 72.9 ± 19.6 9.3 ± 1.8 19.7 ± 5.8 
S1      
Cocaine Dose Response (23) 148 ± 18.6 142.7 ± 
17.5 
70 ± 8.9 11.9 ± 0.8 15.4 ± 2.3 
S2      
Proestrus Potentiation (14) 121.6 ± 15.3 112.3 ± 
11.7 
84.2 ± 16.6 9.7 ± 0.7 12.9 ± 3.7 
S3      
E2 Dose Response (5) 134.3 ± 19.8 170.4 ± 
33.4 
74.5 ± 13.3 11.5 ± 1.5 15.5 ± 3.9 
 
 Figure S1: A two-way independent measures ANOVA showed significant main effects of reinstatement testing 
(extinction vs. reinstatement; F(1,4)=65.584, p<0.001) and a significant interaction between reinstatement day 
and condition (0, 0.625, 1.25, 2.5, 5.0 mg/kg cocaine; F(4,58)=13.902, p<0.001).  Post-hoc testing revealed 
significant reinstatement to 2.5 (p<0.01) and 5.0 (p<0.001) mg/kg cocaine compared to all other doses, with no 
significant difference in reinstatement between 2.5 and 5.0 mg/kg cocaine (p=0.412).  Data are represented as 
mean ± SEM.   
 
  
Figure S2: The adjusted experimental design for testing gonadally-intact females across the estrous cycle is 
found in Figure S2A. A two-way repeated measures ANOVA revealed a significant interaction between day 
(extinction vs. reinstatement) and estrous phase (Figure S2B: estrus = E, metestrus = M, diestrus = D, and 
proestrus = P; F(3,14)=3.927, p<0.05).  Higher responding during reinstatement relative to extinction was observed 
in the proestrus phase of the ovarian hormone cycle (p<0.05).  Data are represented as mean ± SEM.   
 
  
Figure S3: A trend toward a main effect of reinstatement testing (extinction versus reinstatement; F(1,4)=4.948, 
p=0.090), along with a significant interaction between reinstatement testing and condition (0 µg/kg E2/Cocaine, 
10 µg/kg E2/Cocaine, 50 µg/kg E2/Cocaine, 100 µg/kg E2/Cocaine; F(3,12)=5.630, p<0.05) were shown by two-
way ANOVA.  Post hoc testing revealed a strong trend toward higher responding during reinstatement following 
100 µg/kg E2/cocaine versus all conditions (compared to: 0 µg/kg E2/Cocaine, p=0.064; 50 µg/kg E2/Cocaine, 
p=0.066 100 µg/kg E2/Cocaine, p=0.087).  Paired t-test analyses revealed higher reinstatement responding 
relative to extinction in the 100 µg/kg E2/Cocaine condition (t(4)=-3.252, p<0.05).  Data are represented as 
mean ± SEM.   
 
 
